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Abstract
SPL7013 Gel (VivaGel
H) is a microbicide in development for prevention of HIV and HSV. This clinical study assessed retention
and duration of antiviral activity following vaginal administration of 3% SPL7013 Gel in healthy women. Participants
received 5 single doses of product with $5 days between doses. A cervicovaginal fluid (CVF) sample was collected using a
SoftCup
TM pre-dose, and immediately, or 1, 3, 12 or 24 h post-dose. HIV-1 and HSV-2 antiviral activities of CVF samples were
determined in cell culture assays. Antiviral activity in the presence of seminal plasma was also tested. Mass and
concentration of SPL7013 in CVF samples was determined. Safety was assessed by reporting of adverse events. Statistical
analysis was performed using the Wilcoxon signed-rank test with Bonferroni adjustment; p#0.003 was significant. Eleven
participants completed the study. Inhibition of HIV-1 and HSV-2 by pre-dose CVF samples was negligible. CVF samples
obtained immediately after dosing almost completely inhibited (median, interquartile range) HIV-1 [96% (95,97)] and HSV-2
[86% (85,94)], and activity was maintained in all women at 3 h (HIV-1 [96% (95,98), p=0.9]; HSV-2 [94% (91,97), p=0.005]).
At 24 h, .90% of initial HIV-1 and HSV-2 inhibition was maintained in 6/11 women. SPL7013 was recovered in CVF samples
obtained at baseline (46% of 105 mg dose). At 3 and 24 h, 22 mg and 4 mg SPL7013, respectively, were recovered. More
than 70% inhibition of HIV-1 and HSV-2 was observed if there was .0.5 mg SPL7013 in CVF samples. High levels of antiviral
activity were retained in the presence of seminal plasma. VivaGel was well tolerated with no signs or symptoms of vaginal,
vulvar or cervical irritation reported. Potent antiviral activity was observed against HIV-1 and HSV-2 immediately following
vaginal administration of VivaGel, with activity maintained for at least 3 h post-dose. The data provide evidence of antiviral
activity in a clinical setting, and suggest VivaGel could be administered up to 3 h before coitus.
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Introduction
The global human immunodeficiency virus (HIV) epidemic
continues, with an estimated 2.7 million people newly infected
with HIV and 2.0 million dying of acquired immune deficiency
syndrome (AIDS) in 2008 [1]. Women account for half of all
people living with HIV worldwide, increasing to nearly 60% of
HIV infections in sub-Saharan Africa [1]. Vaginally applied
microbicide agents offer a potential strategy for prevention of the
sexual transmission of HIV or other sexually transmitted infections
(STIs) that can be initiated by women. Microbicide classes include
non-specific surfactants or detergents and acid buffering agents,
moderately specific macromolecular anionic polymers that block
HIV and other STIs, and HIV specific drugs that inhibit viral
entry and reverse transcription [2]. A proof of concept study
demonstrating that a vaginal topical microbicide gel containing
1% tenofovir can protect women against HIV acquisition with
39% efficacy compared to placebo gel provides credence to the
development of topical microbicides for HIV prevention [3].
SPL7013 Gel (VivaGelH) is a vaginal microbicide being
developed by Starpharma Pty Ltd (Melbourne, Australia) for the
prevention of HIV and herpes simplex virus (HSV) infections [4].
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24095The active ingredient, SPL7013, is a dendrimer comprising a
divalent benzhydrylamine (BHA) core, four generations of lysine
branches with the outermost branches capped with a total of 32
naphthalene disulfonic acid groups that impart hydrophobicity
and a high anionic charge to the dendrimer surface [5]. SPL7013
has been formulated in a mucoadhesive Carbopol
H-based aqueous
gel for use as a topical vaginal microbicide [6,7].
SPL7013 has broad-spectrum activity against HIV-1 clades and
HIV-2 in vitro [5,8,9] by inhibiting viral attachment and entry
[5,9,10]. In contrast to most linear polyanion microbicides,
SPL7013 demonstrates similar potency against HIV-1 that utilize
the CXCR4 and CCR5 chemokine receptors [5], the latter
accounting for the majority of HIV transmissions [11]. SPL7013 is
active against HIV in cell culture assays in the presence of high
concentrations of serum and cervicovaginal secretions [5], and
retains HIV inhibitory activity when diluted 30-fold in seminal
plasma [9]. SPL7013 also inhibits HIV-1 replication in colorectal
and cervical explant systems against a CCR5 using strain [12,13]
and does not specifically enhance HIV-1 replication in vitro [14].
SPL7013 has low toxicity in cervical and colorectal epithelial cell
lines and lacks the ability to disrupt intracellular tight junctions of
polarized epithelial cells [8].
In a macaque model, SPL7013 Gel was protective against
vaginal challenge with a CXCR4 using simian humanised
immunodeficiency virus (SHIV89.6P) in a dose-related manner
and inhibits replication of the CCR5 using SHIV162P3 strain in
macaque and human peripheral blood mononuclear cells
(PBMCs) [15]. Activity against HSV-1 and HSV-2 has been
demonstrated in vitro [5,10,16], and against HSV-2 infection in
mice and guinea pigs [5,16]. A contraceptive effect of SPL7013
Gel has also been observed in rabbits [4]. SPL7013 Gel is not toxic
as demonstrated in animal models [5,16,17] and in phase I safety
studies in healthy women [18] and men [19].
In order to predict the in vivo efficacy of a microbicide, there has
been a focus on performing pharmacokinetic and pharmacody-
namic studies to evaluate whether a candidate microbicide is
bioavailable and present at levels sufficient to block HIV
replication following vaginal application [20,21,22]. Efficacy
studies of candidate microbicides against vaginal challenge of
SHIV in nonhuman primate models indicate that microbicide
concentrations that are required to prevent in vivo infection are
orders of magnitude greater than the microbicide 50% effective
concentrations (EC50) observed in cell culture [15,23]. Further-
more, seminal plasma diminishes the ability of microbicide
candidates to inhibit HIV and HSV [24,25]. Thus, prior to
performing microbicide efficacy studies in women it is critical to
determine whether levels of microbicide that can be recovered
after vaginal dosing are substantially in excess of the concentra-
tions required to block viral replication in the absence and
presence of seminal plasma. In addition, elucidating antiviral levels
of microbicide that can be recovered as a function of time post-
application is important for predicting whether the microbicide
needs to be applied immediately prior to coitus or whether coitus
can be delayed.
Here we describe the first clinical study of a topical microbicide
that investigates ex vivo antiviral activity and local retention of
SPL7013 Gel over a 24 h period following a single vaginal
application of SPL7013 Gel in women. In addition, cervicovaginal
fluid (CVF) samples were recovered by the participants using the
SoftCup
TM as an alternative to cervicovaginal lavage used in
previous studies to evaluate in vivo microbicide levels [20,21,22].
The rationale for using the SoftCup was to enable self-sampling of
the vaginal vault without introducing an unknown dilution
normally associated with the cervicovaginal lavage method. The
study was performed in healthy, sexually abstinent, HIV-
uninfected women. Our data demonstrate that SPL7013 Gel
was successfully recovered after vaginal dosing from all subjects
and that high-levels of HIV-1 and HSV-2 inhibitory activity were
observed in CVF samples in all participants up to 3 h post-dose,
and in more than 50% of women at 24 h post-dose.
Methods
Study design
The protocol for this study and supporting CONSORT
checklist are available as supporting information; see Checklist
S1 and Protocol S1. The study was an open-label, single centre,
randomised (for order of sampling with the treatment being the
same in each case), 5-period, cross-over study, conducted between
September 2008 and March 2009 at the clinical facilities of
Nucleus Network [Alfred Medical Research and Education
Precinct (AMREP) Centre for Clinical Studies], Melbourne,
Australia. Study participants undertook five single applications of
SPL7013 Gel, each dose separated by a minimum of 5 days. CVF
samples were taken at 0 (within 2–10 min) (baseline), 1, 3, 12 or
24 h post-application in a randomised fashion using the
INSTEAD
H SoftCup
TM. Additional CVF samples were collected
at enrolment prior to dosing (pre-dose sampling period) for
determination of intrinsic antiviral activity and assay validation.
CVF samples were also collected at follow-up (approximately 1
week post final sample) for the determination of SPL7013 levels.
Ethics approval was granted by the Alfred Human Research
Ethics Committee (Drugs and Interventions Committee) on 31
st
July 2008.
Study participants
Female volunteers aged between 18–45 years were recruited by
advertisement, and gave written informed consent to participate.
Participants were eligible if they were not pregnant or breastfeed-
ing, had a regular menstrual cycle, were in good general health as
determined by medical history and physical/pelvic examination
and Pap smear, did not have any sexually transmitted, urinary or
vaginal infections, were not using any vaginal products, and were
using a reliable form of contraception (i.e., sterilisation, inter-
uterine device or non-vaginal hormonal contraception).
Study products
The study was open label. Study product was provided in pre-
filled, single-use applicators containing 3.5 g of gel with 3% by
weight (w/w) of SPL7013 (SPL7013 Gel). SPL7013 Gel is
formulated using Carbopol 971P, a cross-linked acrylic acid listed
in the USP as Carbomer 941 [4]. Participants self-administered
study products at the clinical site, and all used applicators were
retained and counted to check compliance.
Study procedures
A screening visit was conducted up to 28 days prior to
enrolment. During this visit a physical examination was per-
formed, including a pelvic exam (with Pap smear if not performed
in the previous year), vital signs and determination of body mass
index (BMI). Samples were taken for HIV, HSV, hepatitis B virus,
hepatitis C virus, N. gonorrhoeae and C. trachomatis screening,
laboratory assessment (routine biochemistry, haematology and
urinalysis), and pregnancy testing.
Women who fulfilled eligibility criteria and signed informed
consent were enrolled in the trial. The SoftCup
TM (Instead, Inc.,
La Jolla, CA, USA), a commercial menstrual collection device, was
used to collect CVF samples, as previously described [26]. During
Retention of SPL7013 Gel Antiviral Activity
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removing the SoftCup. Each participant was then provided with
three CVF sampling kits (comprising a SoftCup, a 50 mL tube, an
opaque bag marked with participant details and exact weight of
the kit, and an instruction sheet), and discharged from the site.
During the pre-dose sampling period (after the screening visit but
before first dose of study product), participants provided three
separate pre-dose CVF samples. Each sample was taken at least
24 h apart by inserting the SoftCup into the vagina, and then
removing after 10–30 seconds. The used SoftCups containing
CVF samples were then inserted in 50 mL sterile polypropylene
tube and finally sealed in a labelled opaque envelope. Each pre-
dose sample was obtained at the participant’s home and
refrigerated until being packed on ice and couriered to the study
site within 24 h of collection. Once the pre-dose phase was
complete, study participants attended six further visits to the
clinical site. There was one visit each for Treatment Periods 1 to 5,
and a follow-up visit at least one week after the final study
treatment administration.
At Treatment Period 1 eligibility was confirmed, a urine
pregnancy test performed, and each participant was randomised to
one of five different sampling sequences. Each woman adminis-
tered one applicator of SPL7013 Gel, and then obtained a CVF
sample, as before, either immediately post-dose (within 2–10 min)
(baseline); or at 1, 3, 12 or 24 h post-dose, depending upon the
sampling sequence to which she was randomised. These
procedures were repeated during Treatment Periods 2–5, such
that a CVF sample was obtained for each woman at each of the 5
post-dose time-points.
Treatment Periods 1–5 were scheduled during the intra-
menstrual period (at least 2 days prior to or 5 days after the
expected onset of menses), and at least 5 days apart. Each post-
dose CVF sample was obtained at the study site, and participants
were permitted to leave the clinical unit between application and
sample collection except when the baseline or 1 h samples were
collected.
Participants were required to abstain from sexual and vigorous
physical activity for 24 h prior to pre-dose sampling or product
administration, and for the period between product application
and post-dose CVF sampling. Participants were also required to
refrain from administering vaginal preparations throughout the
study period (except tampons, which were permitted for
menstruation outside the product administration and sampling
periods). The exception to this restriction was vaginal treatment of
candidiasis or bacterial vaginosis products, which were permitted if
prescribed by a medical practitioner. In such cases, study visits
were to be suspended until 5 days after the cessation of treatment.
The final status of participants was determined at the follow-up
visit, which included a physical exam (including vital signs and
pelvic exam), laboratory assessment and a pregnancy test. The
final CVF sample was also obtained at this visit for evaluation of
SPL7013 levels. Throughout the study, data were collected on the
participants’ compliance with the study protocol, occurrence of
adverse events (AEs), and administration of any concomitant
medication.
Storage and handling of the cervicovaginal samples
All CVF samples were stored at 4uC until processing, which was
performed within 24 h of obtaining the study sample. The amount
of recovered CVF was determining by calculating the difference
between the combined weight of the 50 ml tube, the used SoftCup
(with recovered CVF) and its original wrapper, and the combined
weight of the unused SoftCup in its wrapper and the 50 ml tube.
The viscosity of SPL7013 Gel made it difficult to quantitatively
remove from the SoftCup. Therefore, to maintain consistency in
the method used for recovery of the immediate pre-dose and post-
dose samples, the CVF sample was washed from the SoftCup
using aliquots of chilled 0.9% sterile phosphate buffered saline
solution totalling 20 mL with shaking and low speed centrifugation
to extract the maximum amount of sample from the cup.
Ciprofloxacin and gentamicin were added to the clarified CVF
samples to a final concentration of 5 mg/mL and 50 mg/mL
respectively, for samples to be evaluated for HIV-1 and HSV-2
inhibitory activity. Samples without antibiotic were used for
determination of the mass of SPL7013. All samples were stored at
280uC prior to analysis.
Evaluation of SPL7013 mass and concentration
The determination of SPL7013 recovery in CVF samples was
performed using a capillary zone electrophoresis method. The
CVF samples were extracted from the SoftCups using a series of
end-to-end rotation and centrifugation steps in the presence of
isotonic saline solution. The SPL7013 and the internal standard,
Orange G (Sigma-Aldrich, Castle-Hill, NSW, Australia), were
monitored at 240 nm on a Beckman P/ACE MDQ capillary
electropherograph (CE) equipped with a diode array detector. The
concentration of SPL7013 in the unknown samples was deter-
mined using a calibration curve derived from samples of known
SPL7013 concentrations. Total mass of SPL7013 present in the
original sample was determined by correcting for the dilution
during processing of the sample. The lower limit of quantitation
for the SPL7013 recovery from the SoftCup and subsequent
analysis was 2.25 mg.
Evaluation of HIV-1 inhibitory activity
The HIV-1 inhibitory activity of pre- and post-dose CVF
samples was determined against HIVBa-L, a laboratory clade B
strain that utilises the CCR5 chemokine coreceptor for viral entry
[27]. Assays were performed in the TZM-b1 indicator cell line
using luciferase as the readout for HIV replication [5]. Tissue
culture plates (96-well, Nunc) were seeded with 20,000 cells per
well the day prior to assay. CVF samples were then diluted 1:2, 1:4
and 1:20 in Opti-MEM (Gibco) containing 0.05 mg/mL ampho-
tericin B (which does not inhibit HIV-1 replication at this
concentration, data not shown), 2.5 mg/mL ciprofloxacin, 50 mg/mL
gentamicin and 20 mg/mL DEAE-dextran, added to triplicate
wells and the plates incubated for 30 min at 37uC in a 5% CO2
humidified incubator. HIV-1Ba-L virus stock, propagated in
PBMCs from HIV seronegative donors, was then added at 500
infectious units (IU)/well and the plates incubated for a further 2
days. HIV-1 replication was assessed by determination of
luciferase activity in cell lysates using the Steady-Glo Luciferase
Assay System (Promega). Virus only and cell controls were
included to determine maximum levels of HIV-1 replication and
background levels of luciferase activity, respectively. The
percentage inhibition of HIV-1 replication in pre-dose and
post-dose samples was calculated by dividing the average
luciferase activity obtained from triplicate wells (after subtracting
background luciferase activity from uninfected cells) by the
luciferase activity obtained from untreated HIV-1Ba-L infected
cells. Unformulated SPL7013 was used as a positive control, and
assays were considered valid if the EC50 fell within two standard
deviations of the mean of previously performed assays
(5.065.2 mg/mL, n=8). The SPL7013 EC50 value was calculat-
ed from nonlinear regression analysis of the data as described
previously [5]. Cytotoxicity of CVF samples was determined at
the same time in duplicate plates to which CVF dilutions but no
virus were added. Cytotoxicity was assessed using the MTS
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described [5]. CVF samples that resulted in cell viability of less
than 80% compared to the cell control were considered cytotoxic
and were not considered for effects on HIV-1 replication. Three
independent valid assays were performed for each CVF sample.
Evaluation of HSV-2 inhibitory activity
The HSV-2 inhibitory activity of CVF samples was deter-
mined in human embryonic lung (HEL) fibroblasts using cell
viability as the readout for viral replication. The HSV-2 isolate
(#250733) [5] that was used in the assay is a highly cytopathic
clinical isolate obtained from an Australian patient and isolated
and typed by the Victorian Infectious Diseases Reference
Laboratory (VIDRL, Melbourne, Australia). Tissue culture
plates (96-well) were seeded with 6,000 cells per well a day
prior to assay and then triplicate wells were incubated with CVF
samples, diluted 1:2, 1:5 and 1:50 in DMEM (Gibco) containing
2 mM glutamine, 25 mM HEPES, 2.5 mg/mL amphotericin B,
10 mg/mL ciprofloxacin, 50 mg/mL gentamicin and 2% foetal
calf serum, for 30 min at 37uCi na5 %C O 2 humidified
incubator, followed by addition of HSV-2 (560 TCID50/well).
The plates were incubated for a further 5 days before HSV-2
replication was assessed by cell viability using the MTS reagent.
Virus and cell only controls were included and cytotoxicity of the
CVF dilutions determined as above. CVF samples that resulted
in cell viability of less than 70% compared to the cell control
were considered cytotoxic and were not considered for effects on
HSV-2 replication. The definition of cytotoxicity for HEL cells
differed to that used for TZM-bl cells due to the sensitivity of
HEL cells to .100 mg/ml of SPL7013 (data not shown). The
percentage inhibition of samples was calculated by subtracting
the average optical density (OD) of samples relative to cell only
controls (after subtracting virus only controls) from 100.
Unformulated SPL7013 was used as a positive control, and
assays were considered valid if the EC50 fell within the range
1.061.3 mg/ml (mean 62SD, n=5). Again, three independent
valid assays were performed for each CVF sample.
Antiviral activity in the presence of seminal plasma
CVF samples from participants 1, 3 and 5, which represented
examples of short, long and intermediate retention times of
complete viral inhibition, respectively, were further analysed in the
presence of pooled seminal plasma from four HIV seronegative
donors (Lee BioSolutions Inc, St. Louis, Missouri). For the
evaluation of HIV-1 inhibitory activity, samples were diluted 1:2
and incubated with TZM-bl cells as above. HIV-1Ba-L was then
added along with seminal plasma to give a final seminal plasma
concentration of 12.5%, a level shown to be non-toxic to TZM-bl
cells (data not shown). To achieve a similar level of luciferase
activity after 2 days incubation to that seen without seminal
plasma, a 4-fold higher inoculum of HIV-1Ba-L was required.
Similar controls to those described above for evaluation of anti-
HIV-1 activity were again included and three independent assays
performed.
For the evaluation of HSV-2 inhibitory activity, CVF samples
were diluted to 1:50 and added to HEL cells as described above.
HSV-2 was then added in the presence of a final concentration of
10% seminal plasma and the cells incubated for 5 days as
described above. 10% seminal plasma was shown to be non-toxic
to HEL cells over this period. For HSV-2 assays, a 2-fold higher
inoculum was required compared to assays performed in the
absence of seminal plasma to achieve the same level of baseline
infection.
Contribution of SPL7013 to the antiviral activity of
SPL7013 Gel
To determine the contribution of SPL7013 to the antiviral
activity of SPL7013 Gel present in the CVF samples of
participants, 2 g of SPL7013 Gel or Placebo Gel (being the same
formulation but absent of SPL7013) and 0.5 g of pooled CVF
samples from four HIV seronegative donors (Lee BioSolutions)
were thoroughly mixed with 20 mL saline to mimic the maximum
amount of gel recovered in post-dose samples, and the average
amount of CVF collected in pre-dose samples. Following
centrifugation, as for the recovery of CVF samples, the gel/CVF
mixtures were compared for their anti-HIV-1 activity at 1:2, 1:4,
1:20, 1:100 and 1:200 dilutions in TZM-bl cells, and for anti-
HSV-2 activity at 1:2, 1:5, 1:50, 1:100 and 1:200 dilutions in HEL
cells, as described above. Cytotoxicity of the dilutions in the two
cell lines was also assessed using the MTS reagent. Three
independent assays were performed with each virus.
Assessment of safety
Safety was assessed from reports of adverse events (AEs), vital
signs and routine laboratory assessment. An AE was described as
any untoward medical occurrence in a subject administered an
investigational product, and which does not necessarily have a
causal relationship to the study drug. All AEs reported during the
study were graded according to the Division of AIDS Genital
Grading Table for Use in Microbicide Studies and the Division of
AIDS Table for Grading the Severity of Adult and Paediatric
Adverse Events, including Addendum 1 Female Genital Grading
Table for Use in Microbicide Studies [28] and assigned a potential
causality to study product.
Statistical methods
The sample size was considered typical of a study assessing
pharmacokinetic parameters as the primary endpoints, and was
also similar to sample sizes employed in the two similar studies
assessing antiviral activity of the microbicide PRO 2000 [20,21].
Comparison of parameters for the 1, 3, 12 and 24 h CVF samples
with those for the baseline sample, were performed initially using a
Friedman test to assess overall differences between timepoints.
Pairwise comparisons were then assessed using the Wilcoxon
signed-rank test for repeated measures data with Bonferroni
adjustment, where p#0.003 was statistically significant (STATA
version 11, StataCorp, College Station, TX, US). The impact of
seminal plasma and relative effects of placebo compared to
SPL7013 Gel on antiviral activity was performed using the
Wilcoxon signed-rank test (one-sided) (GraphPad PRISM version
4, GraphPad Software, San Diego, CA, USA), where p,0.05 was
considered statistically significant. In the case of non-significant
associations/differences, with the limited sample size of the study,
there is insufficient evidence to be able to demonstrate a
difference, if indeed such a difference does truly exist.
Results
Enrolment and adverse events
Twelve eligible women were enrolled in the study. Ten
completed CVF sampling for all 5 time-points. An additional
woman completed four time-points, including the baseline sample,
and therefore was included in the Per Protocol analysis. One of the
12 participants was lost to follow up due to reasons unrelated to
AEs or study procedures. Participants were aged between 19–37
years old (mean 25 years old), with a BMI ranging from 18.2 to
30.3 (mean 23.5). All women were using hormonal contraception
at baseline, and continued throughout the study.
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laboratory parameters during the study. No grade 3 or 4 AEs,
serious AEs or deaths were reported during the study. Eight non-
genitourinary AEs (mainly grade 1) were experienced by six
subjects (50%), all of which were considered not related to study
product. Seven genitourinary AEs were experienced by four
subjects (33.3%) who received at least one dose of 3% SPL7013
Gel. Two of the AEs reported were considered likely related to
SPL7013 Gel administration and were perineal irritation (Grade 1)
and bacterial vaginosis (Grade 2). The only reported AEs
considered to be possibly related to 3% SPL7013 Gel adminis-
tration were three cases of clinical symptoms of vaginal candidiasis
in three subjects (Grade 1). All other AEs were deemed unlikely to
be related to SPL7013 Gel and were Grade 1 in severity. No
trends were observed for the time of onset of AE, or randomisation
sequence for CVF sampling time.
Recovery of CVF sample using the SoftCup self-sampling
method
The average weight 6 standard deviation of CVF sample
recovered pre-dose from 11 participants was 0.4460.27 g (range
0.14–1.06 g), which is similar to a previous study [26]. The mean
% (standard error) recovery of post-dose CVF sample (including
gel) compared to the weight of SPL7013 Gel application (3.5 g) for
first, second, third, fourth and fifth samples (i.e., the randomized
sequence in which each sample was taken irrespective of the time-
point) for all participants was 46% (6.7), 51% (6.3), 55% (8.3), 52%
(9.8) and 40% (6.2), respectively (Figure 1A). There were no
significant differences in recovery between the post-dose samples
(p.0.20 in each case, Wilcoxon signed-rank test), indicating
consistency of sampling.
We also evaluated the mean % weight of the recovered post-
dose CVF samples compared to the weight of the original sample
of SPL7013 Gel with respect to time post dose (Figure 1B). A time-
dependent decrease in the weight of recovered CVF was observed
with a mean 75% of the original sample recovered at baseline,
which plateaued at 12 h (30%) and 24 h (31%) post-dose. These
data demonstrate consistent collection of CVF samples using the
SoftCup and a time dependent decrease in the weight of recovered
sample.
Recovery of SPL7013 using the SoftCup self-sampling
method
We determined the mass of SPL7013 that was recovered
compared to the mass of SPL7013 dosed (i.e., 105 mg) for each
participant at each time point (Figure 2A). At baseline, a 48 mg of
the original dose (mean) was recovered representing 46% of the
original mass of SPL7013 applied to the vagina (Figure 2B). The
mean % recovery compared to the original mass of SPL7013 at
times 1, 3, 12 and 24 h post dose was 42, 21, 6.8 and 3.9%,
respectively (Figure 2B). This represents 90, 46, 15 and 9%
recovery compared to the baseline post-dose CVF sample,
respectively. These data demonstrate that the mass of recovered
SPL7013 decreases with time and that a large proportion of the
original SPL7013 (.20%) dose can be recovered at 1 and 3 h
following SPL7013 Gel administration.
HIV-1 inhibitory activity of pre- and post-dose CVF
samples
The ability of pre- and post-dose samples to inhibit HIV-1
replication was determined in the TZM-bl indicator cell line.
CVF samples recovered in 20 mL of saline were subjected to an
additional 1:2 dilution in medium, representing a total dilution
of ,1:40 of the neat CVF sample, which was not cytotoxic to
TZM-bl cells used to evaluate HIV-1 inhibitory activity. Since
CVF samples obtained at the final non-dosing study visit were
found to have undetectable levels of SPL7013, they were not
evaluated for antiviral activity. The median (interquartile range)
inhibition of HIV-1 by pre-dose CVF samples was 1.9% (0, 5.6).
In contrast, almost complete HIV-1 inhibition was observed with
baseline CVF samples (Figure 3A), where a median (interquartile
range) inhibition of 96% (95, 97) was achieved. The 1, 3, 12 and
24 h CVF samples provided a median inhibition of 96% (95, 99)
(p=0.77), 96% (94, 98) (p=0.91), 88% (20, 97) (p=0.003) and
88% (0, 96) (p=0.001), respectively. Inhibition of HIV
replication at 1 and 3 h post-dose was not significantly different
(defined as p#0.003, Bonferroni adjusted p-value significance
level) compared to the baseline CVF sample. There was a
significant drop in median inhibition observed at 12 and 24 h
post-dose, which was due to reductions in the ability of recovered
CVF samples from five women to inhibit HIV-1 (Figure 3A).
HSV-2 inhibitory activity of pre- and post-dose CVF
samples
The pattern of HSV-2 inhibitory activity was very similar to
that for HIV-1 (Figure 3B). Anti-HSV-2 activity was low at pre-
Figure 1. Recovery of CVF samples using the SoftCup. Weight of
post-dose CVF samples as a percentage of the actual weight of SPL7013
Gel administered vaginally compared to the position in the sampling
sequence (A) and the time post-dose (B). Data represent the average
from the eleven study subjects. Error bars denote standard error of the
mean.
doi:10.1371/journal.pone.0024095.g001
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0.6% (0, 1.5) and 86% (85, 94), respectively. Median HSV-2
inhibition for the 1, 3, 12 and 24 h samples was 92% (79, 100)
(p=0.237), 94% (90, 99) (p=0.005), 96% (0,100) (p=0.027) and
75% (0, 100) (p=0.756), respectively. Similar to HIV-1, there was
no significant difference in anti-HSV-2 activity (defined as
p#0.003, Bonferroni adjusted p-value significance level) at 1 and
3 h post-dose compared when data was analysed using the
Wilcoxon signed-rank test with Bonferroni adjustment. In contrast
to HIV-1, the difference between median inhibition at baseline
and that seen at either 12 or 24 h did not reach, but tended
towards, statistical significance for HSV-2. In contrast to the HIV-
1 inhibition assays, CVF samples recovered in 20 ml of saline were
diluted an additional 1 in 50 for evaluation of HSV-2 inhibitory
activity since this was the lowest dilution that was noncytotoxic to
the HEL cells used in the assay.
Impact of seminal plasma on HIV-1 and HSV-2 inhibitory
activity of post-dose CVF samples
Seminal plasma can mediate adverse effects on the antiviral
activity of microbicides [24,25]. We selected CVF samples from
participants displaying three different patterns of HIV-1 and
HSV-2 inhibition representing short (subject 1), intermediate
(subject 5) and long (subject 3) retention times of complete
inhibition (Figure 4). These samples were tested to determine
whether the addition of seminal plasma diminished inhibition of
viral replication compared to samples that we had tested in the
absence of seminal plasma.
We did not observe a decrease in the ability of CVF samples
from the three subjects to block HIV-1 replication compared to
baseline at 1 and 3 h post-dose in the presence of seminal
plasma compared to no seminal plasma (Figure 4A, B and C).
O n ee x c e p t i o nw a st h e3 hp o s t - d o s es a m p l ef o rs u b j e c t5 ,
where the decrease in HIV-1 inhibition observed in the presence
of seminal plasma tended towards significance (p=0.054, n=3,
Wilcoxon signed-rank test) and was minimal in the context of
this type of biological assay (average decrease of 4.5%)
(Figure 4C). In addition, seminal plasma did not decrease the
HIV-1 inhibitory activity of CVF samples from subject 3
obtained at 12 and 24 h post-dose (Figure 4B). In contrast,
seminal plasma conferred a significant decrease in HIV-1
inhibition, which tended towards significance with CVF samples
f r o ms u b j e c t s1a n d5t a k e na t1 2hp o s t - d o s e( p=0 . 0 6 2 ,n=3 )
(Figure 4A and C).
Figure 2. Recovery of SPL7013 using the SoftCup. Mass of SPL7013 (mg) recovered in CVF samples from each subject taken at baseline (within
2–10 minutes post-dose) (0), 1, 3, 12 and 24 h post-dose (A). Average recovery of SPL7013 as a percentage dose of SPL7013 administered (105 mg)
(B). Error bars denote standard error of the mean.
doi:10.1371/journal.pone.0024095.g002
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24095A similar pattern was also observed for inhibition of HSV-2 for
subjects 1 and 3, where there was no significant decrease of HSV-2
inhibitory activity in the presence of seminal plasma compared to
no seminal plasma with CVF samples taken at baseline, 1 and 3 h
post-dose (Figure 4D and E). Subject 5 was the exception, where
there was a drop in HSV-2 inhibition tending towards significance
for the 3 h sample (p=0.062, n=3) (Figure 4F). These data
demonstrate that for the majority of patients, seminal plasma had
little effect on the ability of the CVF samples to inhibit HIV-1 and
HSV-2 replication at up to 3 h post-dose.
Relationship between recovered SPL7013 mass or
concentration and HIV-1 and HSV-2 inhibitory activity in
CVF samples
We plotted the total mass of recovered SPL7013 against HIV-1
(Figure 5A) and HSV-2 inhibition (Figure 5B) mediated by post-
dose CVF samples. The inhibition of HIV-1 (Figure 5C) and
HSV-2 (Figure 5D) as a function of SPL7013 concentration was
also analysed. High levels of anti-HIV-1 activity (i.e., .94%
inhibition) were observed when .9 mg of SPL7013 was present in
CVF samples and .70% inhibition was achieved with as little as
0.5 mg of SPL7013. These levels represent 8.6% and 0.5% of the
total mass of SPL7013 applied to the vagina, respectively
(Figure 5A). High levels of anti-HSV-2 activity (i.e., $80%
inhibition) was observed with .2.5 mg of SPL7013, representing
2.4% of the original dose (Figure 5B). A lower cut off for maximal
inhibition of HSV-2 compared to HIV-1 replication was necessary
due to cytotoxicity to HEL cells mediated by high concentrations
of SPL7013 (.35 mg) that was also observed in our pilot studies.
Greater than 80% HIV-1 (Figure 5C) and HSV-2 (Figure 5D)
inhibition was observed if at least 0.2% of the dosed SPL7013 was
present in the original CVF sample. This represents ,50 ng/ml of
SPL7013 when taking into consideration the ,1:40 dilution of the
samples for HIV-1, and ,2 ng/ml when taking into account the
,1:1000 dilution required for testing CVF samples in the HSV-2
assays. These data show that SPL7013, at levels representing a
fraction of the original dose, demonstrates high levels of HIV-1
and HSV-2 inhibitory activity in ex vivo assays despite extensive
dilution of the CVF samples by ,1:40 and ,1:1000, respectively.
Contribution of SPL7013 to the antiviral activity of
SPL7013 Gel
The Placebo Gel is identical to SPL7013 Gel except for the
absence of SPL7013. Thus, the Placebo gel comprises a Carbopol
Figure 3. HIV-1 and HSV-2 inhibitory activity of post-dose CVF samples. The percent inhibition of HIV-1 replication mediated by post-dose
CVF samples from each subject compared to HIV-1 infected cells incubated in the absence of CVF sample. All samples recovered in 20 mL of saline
were diluted an additional 1:2 (total dilution of samples , 1:40) (A). The percent inhibition of HSV-2 replication mediated by post-dose CVF samples
from each subject compared to HSV-2 infected cells incubated in the absence of CVF sample. All samples recovered in 20 mL of saline were diluted
an additional 1:50 (total dilution of samples , 1:1000) (B). Data are from three independent assays. Error bars denote standard error of the mean.
doi:10.1371/journal.pone.0024095.g003
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24095Figure 4. Impact of seminal plasma on the HIV-1 and HSV-2 inhibitory activity of post-dose CVF samples. Inhibition of HIV-1 replication
by post-dose CVF samples from subjects 1 (A), 3 (B) and 5 (C) performed in the absence and presence of 12.5% seminal plasma (SP). Inhibition of HSV-
2 replication by post-dose CVF samples from subjects 1 (D), 3 (E) and 5 (F) performed in the absence and presence of 10% seminal plasma. Data are
from three independent assays. Error bars denote standard error of the mean.
doi:10.1371/journal.pone.0024095.g004
Figure 5. Relationship between recovered mass and concentration of SPL7013, and HIV-1 and HSV-2 inhibitory activity of post-
dose CVF samples. The inhibition of viral replication in post-dose CVF sample from all participants as a function of either the mass of recovered
SPL7013 for HIV-1 (A) and HSV-2 (B) or the concentration of SPL7013 in the original undiluted samples for HIV-1 (C) and HSV-2 (D).
doi:10.1371/journal.pone.0024095.g005
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activity [29,30,31]. Therefore, to determine the contribution of
SPL7013 in the SPL7013 Gel formulation to the antiviral activity
of CVF samples obtained in the study, in vitro experiments with
Placebo Gel were performed to mimic the assays performed with
CVF samples from the trial participants. Either 2 g of either
SPL7013 Gel or Placebo Gel were combined with 0.5 g of pooled
CVF samples. These samples where then processed as described
for the participant CVF samples, except that we investigated
additional sample dilutions (Figure 6A and B). In parallel, assays
were performed to determine doses that were not toxic to the cells
used in the antiviral assays to identify dilutions that could be
evaluated for antiviral activity (Figure 6C and D).
The data reported here show similar levels of HIV-1 inhibition
by SPL7013 Gel and Placebo Gel diluted at 1:2 and 1:4
(Figure 6A). In contrast, $90% HIV-1 inhibition by SPL7013
Gel was observed at 1:20, 1:100 and 1:200 dilution while
inhibition was lower in the presence of Placebo Gel, which tended
towards significance (p=0.05). No cytotoxicity was observed for
either gel formulation at any of the dilutions tested (Figure 6C).
The HIV-1 inhibitory activity of post-dose CVF samples that were
diluted 1:20 compared to the 1:2 dilution (Figure 3A) demon-
strated similar high levels of HIV inhibition ($85%) for all
participants up to 3 h post-dose (data not shown). These data
indicate that the HIV-1 inhibitory activity of CVF samples can be
observed at dilutions where SPL7013 Gel (and thus SPL7013), but
not Placebo Gel is inhibitory (Figure 6A).
Significant cytotoxicity is observed in cells used in the HSV-2
inhibitory assays at 1:2 and 1:5 dilutions for both SPL7013 Gel
and Placebo Gel (compromising the ability to assess HSV-2
inhibition at these dilutions), but not at the 1:50 dilution or greater
(Figure 6D). Cytotoxicity was absent at and above 1:50 dilution
and these dilutions could thus be evaluated for anti-HSV-2
activity. SPL7013 Gel demonstrated high levels of HSV-2
inhibition compared to Placebo Gel, which lacked inhibitory
activity at 1:50, 1:100 and 1:200 dilutions (Figure 6B). Since post-
dose CVF samples from all participants were tested at a 1:50
dilution in the anti-HSV-2 assays (Figure 3B), the inhibition
observed in our cell culture assays is almost certainly due to
SPL7013 and not the vehicle (Placebo Gel). Taken together, these
data indicate that both SPL7013 and Placebo Gel are likely to
contribute to HIV-1 inhibitory activity, however SPL7013-
containing gel retains HIV-1 and HSV-2 inhibitory activity upon
significant dilution.
Discussion
This study demonstrates for the first time the retention of HIV-1
and HSV-2 inhibitory levels of SPL7013 Gel in the female genital
tract over a 24 h period. The strength of this study compared to
previous studies of microbicide vaginal pharmacokinetics and
pharmacodynamics [20,21] is that we followed the time course of
retention of antiviral activity present in recovered CVF samples
after a single dose of microbicide, in addition to determining the
concentrations of SPL7013 present in recovered CVF samples
with time. Furthermore, the SoftCup was effectively used for the
recovery of CVF samples instead of cervicovaginal lavage, thus
allowing direct calculation of the degree of sample dilution. Our
Figure 6. Contribution of SPL7013 to antiviral activity in SPL7013 Gel. Inhibition of HIV-1 (A) and HSV-2 (B) replication of 2 g of SPL7013 Gel
or Placebo Gel combined with 0.5 g of pooled human cervicovaginal secretions and diluted in 20 mL of saline. Cytotoxicity of the samples in TZM-bl
cells (C) and HEL cells (D). Dilution denotes fold dilutions of CVF sample in medium that were initially recovered in saline. Data are from three
independent assays. Error bars denote standard error of the mean.
doi:10.1371/journal.pone.0024095.g006
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level HIV-1 and HSV-2 inhibitory activity in the post-dose CVF
samples in all participants, was 3 h after a single dose of SPL7013
Gel. Remarkably, the CVF samples from the majority of
participants (6/11) also demonstrated high levels ($80% inhibi-
tion) of antiviral activity at 24 h post-dose. Quantitation of the
mass of SPL7013 recovered from CVF samples showed that
.9 mg and .2.5 mg of SPL7013 was associated with high levels
of HIV-1 and HSV-2 inhibition, respectively, representing a small
fraction of the original 105 mg dose of SPL7013 in SPL7013 Gel.
Notably, antiviral activity was retained in the presence of seminal
plasma for the majority of the participants up to 3 h post-dose
indicating that dosing of SPL7013 Gel up to 3 h prior to coitus
could be incorporated in clinical trials evaluating microbicide
efficacy.
Consistent with previous phase I safety studies, SPL7013 Gel
demonstrated no serious AEs, nor Grade 3 or 4 AEs, and the
genitourinary AEs were mainly mild in severity [18,19]. No trends
were observed for the time of onset of AE or randomisation
sequence for CVF sampling time and there were no withdrawals
due to AEs.
Remarkably, prolonged retention of HIV-1 and HSV-2
inhibitory activity was observed in the CVF samples from the
majority of participants at 12 (8/11) and 24 h (6/11) post-dose.
SPL7013 is formulated in a Carbopol vehicle that has mucoadhe-
sive properties, which may extend its retention in the female
genital tract. However, it is not clear why some women
demonstrated prolonged retention of SPL7013 compared to
others. The women, while ambulatory, were instructed to abstain
from sex and not undertake physical exercise, such as running,
that could promote clearance of the gel from the vagina. Natural
variations in anatomical shape of the vagina may have contributed
to the difference in retention. It is also possible that women
experiencing lower SPL7013 retention times may have experi-
enced vaginal child-birth, thus weakening the pelvic floor.
However, such data was not collected from the participants and
therefore it would be interesting to examine this possibility in
future studies.
A limitation of this study is that, in order to determine HIV-1
and HSV-2 inhibitory levels in recovered pre- and post-dose CVF
samples, it was necessary to dilute the samples. This was because
the assays were cell culture based and our pilot studies
demonstrated that cervicovaginal secretions, the gel vehicle and
moderately high concentrations of SPL7013 (in the case of HEL
cells) reduced cell viability and therefore would interfere with the
evaluation of antiviral levels in the CVF samples. Accordingly, we
performed antiviral and cytotoxicity assays in parallel and three
independent assays to obtain robust data for analysis. The total
dilution of the 1:2 and 1:50 CVF samples tested in the HIV-1 and
HSV-2 inhibition assays was approximately 1:40 and 1:1000
respectively, after taking into consideration dilution of the sample
with 20 mL of sterile saline that was essential for quantitative
removal of sample from the SoftCup. This compares to final
(estimated) dilutions of 1:20 and 1:40 in PRO 2000 samples
recovered after vaginal application by cervicovaginal lavage using
10 mL of saline [20]. Given the considerable dilution of CVF
samples, virus inhibition observed for pre- and post-dose samples
are likely to be an underestimate of the actual activity and quantity
of the product in the genital tract. CVF sample dilution could also
explain why we did not observe intrinsic HIV-1 [32] and HSV-2
[33] inhibitory activity in pre-dose CVF samples from all
participants similar to that observed in a previous study with
PRO 2000 [20]. Extensive dilution of our CVF samples is also
likely to underestimate the length of duration of high levels of
antiviral activity.
PRO 2000 is a linear macromolecular polyanion microbicide,
which has undergone similar studies to determine the retention of
antiviral levels of microbicide after intravaginal dosing in women,
except that samples were recovered by cervicovaginal lavage with
10 mL of saline and only single time points were evaluated
[20,21]. For the 0.5% PRO 2000 dose, 6.6% recovery of PRO
2000 was achieved for the 2 h post-dose samples [21] and 5.8 –
17% recovery for 0.5% PRO 2000 at 1 h post-dose [20] using the
same calculation as described by Lacey and colleagues [21]. Using
the SoftCup we achieved an average 41% recovery (50 mg) of the
original 105 mg dose of SPL7013 in the 1 h post-dose CVF
samples, which is substantially greater than the highest recovery
reported for 0.5% PRO 2000. In addition, the baseline post-dose
recovery of SPL7013 was 46%. The SoftCup method’s recovery of
a robust fraction of the recently applied SPL7013 increases
confidence in its effective recovery of the intraluminal drug. The
SoftCup has a soft elastomeric rubber rim surrounding a collection
dome, which when inserted and removed from the vagina has a
spatula-like action that may more efficiently collect viscous fluids
from the vaginal lumen than does cervicovaginal lavage. However,
complete recovery of SPL7013 Gel was not achieved even for
baseline post-dose CVF samples. SPL7013 loss is unlikely to be
due to systemic absorption [4]. Thus, SPL7013 Gel may have
been lost due to leakage from the vagina, inaccessibility to the
SoftCup or remained non-specifically bound to the epithelial cells
lining the female genital tract. Our data also show that use of the
SoftCup leads to reproducible sample recovery independent of the
sampling sequence, allows direct calculation of the extent of
sample dilution, and can be self administered by the participant
following minimal instruction, thus representing a promising
alternative to cervicovaginal lavage.
Levels of PRO 2000 that were sufficient to block HIV-1
infection in cell culture assays were recovered from retention
studies with 0.5% PRO 2000 [20,21]. However, this formulation
failed to demonstrate significant protection in preventing HIV
acquisition in phase IIB and III clinical trials [34,35]. The
dendrimer, SPL7013, has a chemically defined structure and a
distinct surface group compared to polymeric linear polyanion-
based microbicides such as PRO 2000. In the 3.5g dose of 3%w/w
SPL7013 Gel there is an approximate 20,000-fold excess of
SPL7013 delivered to the female genital tract compared with the in
vitro EC50 for HIV clinical isolates and an approximate 45,000-fold
excess of SPL7013 compared with the in vitro EC50 for a HSV-2
clinical isolate [5]. Compared to 2 g of 0.5% PRO 2000 [21],
SPL7013 Gel delivers a 10.5-fold higher mass of active drug at
levels that are tolerated in vivo [18]. Our retention study shows that
in baseline, 1 and 3 h post-dose CVF samples we were able to
recover an average 48, 43 and 22 mg of SPL7013, respectively.
This represents SPL7013 levels (even when diluted in semen and
CV secretions) that are at least 10
3-fold greater than the cell
culture EC50 for inhibition of both HIV-1 and HSV-2. In previous
studies, a 1:30 dilution of SPL7013 Gel retained anti-HIV activity
in the presence of seminal plasma retained anti-HIV activity in cell
culture assays [9]. Consistent with this observation, the HIV-1 and
HSV-2 inhibitory activities of recovered CVF samples in this study
remained high for the majority of participants up to 3 h post dose
even when assays were performed in the presence of seminal
plasma. However, other factors that could affect the efficacy of a
gel based macromolecular microbicide, apart from dilution or
inhibition by genital secretions, includes its re-distribution within
the vagina, which may also be affected by stirring during the act of
coitus [22], which was not assessed in this study. As significant
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percentage of the original dose of SPL7013, it can be theorised
that the effects of coitus would not significantly impact the activity
of the product. However this could only be established with further
clinical investigation. Nevertheless, in the proof of concept study
demonstrating that a topical microbicide gel containing 1%
tenofovir protected women against HIV acquisition with 39%
efficacy compared to placebo gel, more HIV negative women had
detectable CVF concentrations of tenofovir, and tenofovir
concentrations in CVF were associated with reduced risk of HIV
and HSV-2 infection [36].
In conclusion, we have demonstrated retention of high-level
HIV-1 and HSV-2 inhibitory activity of a dendrimer microbicide
following vaginal administration that is long-lived in the majority
of participants. While efficacy trials will be required to determine
whether SPL7013 Gel is able to protect women against HIV and
HSV acquisition, the concentration of drug in CVF samples is a
potentially important means to determine target drug concentra-
tions for providing protection and is a potential surrogate marker
for protection.
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